Overview
NICE is unable to make a recommendation on recombinant human parathyroid hormone for treating hypoparathyroidism because Shire Pharmaceuticals (now part of Takeda) did not provide an evidence submission.
Last reviewed: 4 March 2020
Next review: We will review this decision if the company decides to make a submission.